Wei Keith Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wei Keith Tan has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Rebecca C. Fitzgerald
Early Cancer Institute, University of Cambridge, Cambridge, UK
3 shared publications Massimiliano di Pietro
2 shared publications- Massimilliano di Pietro
Early Cancer Institute, University of Cambridge, Cambridge, United Kingdom
2 shared publications - Peter Sasieni
Queen Mary University of London
2 shared publications Adam G. Berman
Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
1 shared publicationAndreas V. Hadjinicolaou
MRC Cancer Unit, University of Cambridge, Cambridge, UK
1 shared publication
Latest Publications
- Open Access
- 7 May 2024
- Published by Elsevier in Gastroenterology
- Vol. 167 (4) , 798-800.e4
Targeted Screening for Barrett’s Esophagus and Esophageal Cancer: Post Hoc Analysis From the Randomized BEST3 Trial
- 7 May 2024
- Published by Elsevier in Gastroenterology
- Vol. 167 (4) , 798-800.e4
Open AccessTargeted Screening for Barrett’s Esophagus and Esophageal Cancer: Post Hoc Analysis From the Randomized BEST3 Trial
- Open Access
- 1 February 2023
- Published by Elsevier in Techniques and Innovations in Gastrointestinal Endoscopy
- Vol. 25 (2) , 146-156
The Horizon of Screening for Barrett's Esophagus and Esophageal Cancer
- 1 February 2023
- Published by Elsevier in Techniques and Innovations in Gastrointestinal Endoscopy
- Vol. 25 (2) , 146-156
Open AccessThe Horizon of Screening for Barrett's Esophagus and Esophageal Cancer
- Open Access
- 15 July 2022
- Published by Elsevier in EBioMedicine
- Vol. 82, 104160
Quantification of TFF3 expression from a non-endoscopic device predicts clinically relevant Barrett's oesophagus by machine learning
- 15 July 2022
- Published by Elsevier in EBioMedicine
- Vol. 82, 104160
Open AccessQuantification of TFF3 expression from a non-endoscopic device predicts clinically relevant Barrett's oesophagus by machine learning
O6 Ideal age to screen for Barrett’s oesophagus and oesophageal adenocarcinoma: modelling from the cytosponge-BEST3 trial
Introduction Screening for Barrett’s oesophagus (BO) is a consideration due to the high mortality from oesophageal adenocarcinoma (OAC). The aim of this study was to utilise data from the randomised controlled Barrett’s oEsophagus Screening Trial 3 (BEST3) to estimate: 1) the optimal age for screening of BO/OAC; and 2) the number of missed cases under current primary care reflux referral pathway. Methods Individuals in the BEST3 who swallowed the Cytosponge (n=1654) were included. For aim 1, we used the positive-predictive value (PPV) of the Cytosponge for a diagnosis of BO/OAC as a proxy for the disease prevalence in the community and modelled the probability of a diagnosis of BO/OAC. Both analyses were stratified by age and sex. For aim 2, we used the BEST3 intervention (n=6834) and control arm (n=6388) data to estimate the number of missed BO/OAC under current reflux referral pathway. Results Using a 5% risk cut-off for undiagnosed BO/OAC, the ideal age for screening males and females with reflux is 55–79, and 65–79 years, respectively (Figure 1). The overall PPV for a diagnosis of BO/OAC were 65% (95% CI 57–73%) for males and 50% (95% CI 39–61%) for females. The number of missed BO/OAC was estimated using BEST3 data. There were 16/6388 (0.3%) and 131/6834 (1.9%) cases of BO/OAC diagnosed among those randomised to usual care or who had the Cytosponge, respectively. If we correct for those who were: randomised to the Cytosponge group but did not accept the offer (5180/6834, 78.8%); unable to swallow the Cytosponge (96/1750, 5.5%); declined confirmatory endoscopy (10/231, 4.3%); and those with a false negative diagnosis - based on the random sample who were invited for endoscopy at end of the study among the TFF3 negative group (2/64, 3.1%); we estimate that 680 cases of BO/OAC among the 6388 individuals in the controls, and 500 of these could have been screen-detected if all had attempted to swallow a Cytosponge. Compared to 16 cases of BO/OAC identified through usual care, 97.6% of BO/OAC are likely to be missed using the current referral pathway and 73.5% of undiagnosed disease could be detected by screening. Probability of a diagnosis of BO or OAC by age, stratified by gender. Dashed lines represent 3% and 5% risk cut-off for BO or OAC Conclusion A Cytosponge-based screening strategy for BO/OAC could include males aged 55–79 and females aged 65–79; depending on uptake rates, it would allow us to discover a greater proportion of the 97.6% estimated missed BO/OAC in the community.
O6 Ideal age to screen for Barrett’s oesophagus and oesophageal adenocarcinoma: modelling from the cytosponge-BEST3 trial
Introduction Screening for Barrett’s oesophagus (BO) is a consideration due to the high mortality from oesophageal adenocarcinoma (OAC). The aim of this study was to utilise data from the randomised controlled Barrett’s oEsophagus Screening Trial 3 (BEST3) to estimate: 1) the optimal age for screening of BO/OAC; and 2) the number of missed cases under current primary care reflux referral pathway. Methods Individuals in the BEST3 who swallowed the Cytosponge (n=1654) were included. For aim 1, we used the positive-predictive value (PPV) of the Cytosponge for a diagnosis of BO/OAC as a proxy for the disease prevalence in the community and modelled the probability of a diagnosis of BO/OAC. Both analyses were stratified by age and sex. For aim 2, we used the BEST3 intervention (n=6834) and control arm (n=6388) data to estimate the number of missed BO/OAC under current reflux referral pathway. Results Using a 5% risk cut-off for undiagnosed BO/OAC, the ideal age for screening males and females with reflux is 55–79, and 65–79 years, respectively (Figure 1). The overall PPV for a diagnosis of BO/OAC were 65% (95% CI 57–73%) for males and 50% (95% CI 39–61%) for females. The number of missed BO/OAC was estimated using BEST3 data. There were 16/6388 (0.3%) and 131/6834 (1.9%) cases of BO/OAC diagnosed among those randomised to usual care or who had the Cytosponge, respectively. If we correct for those who were: randomised to the Cytosponge group but did not accept the offer (5180/6834, 78.8%); unable to swallow the Cytosponge (96/1750, 5.5%); declined confirmatory endoscopy (10/231, 4.3%); and those with a false negative diagnosis - based on the random sample who were invited for endoscopy at end of the study among the TFF3 negative group (2/64, 3.1%); we estimate that 680 cases of BO/OAC among the 6388 individuals in the controls, and 500 of these could have been screen-detected if all had attempted to swallow a Cytosponge. Compared to 16 cases of BO/OAC identified through usual care, 97.6% of BO/OAC are likely to be missed using the current referral pathway and 73.5% of undiagnosed disease could be detected by screening. Probability of a diagnosis of BO or OAC by age, stratified by gender. Dashed lines represent 3% and 5% risk cut-off for BO or OAC Conclusion A Cytosponge-based screening strategy for BO/OAC could include males aged 55–79 and females aged 65–79; depending on uptake rates, it would allow us to discover a greater proportion of the 97.6% estimated missed BO/OAC in the community.
- 25 February 2022
- Published by S. Karger AG in Visceral Medicine
- Vol. 38 (3) , 161-167
Barrett’s Oesophagus: Today’s Mistake and Tomorrow’s Wisdom in Screening and Prevention
Background: Oesophageal adenocarcinoma (OAC) is a lethal cancer with an overall 5-year survival of Summary: New research on the use of epidemiologic and clinical data has allowed the creation of risk-prediction algorithms to identify the population at risk. In addition, newer less-invasive devices such as transnasal endoscopy, Cytosponge, volumetric laser endomicroscopy, and volatile organic compounds are emerging as promising options to allow screening in the primary care setting. Finally, there is an opportunity to intervene at the pre-invasive stage with pharmacological strategies to reduce the risk burden. Key Messages: In this review, we provide a critical appraisal of the different screening approaches and chemopreventive strategies and a guide to readers on how to implement research evidence in clinical practice.
- 25 February 2022
- Published by S. Karger AG in Visceral Medicine
- Vol. 38 (3) , 161-167
Barrett’s Oesophagus: Today’s Mistake and Tomorrow’s Wisdom in Screening and Prevention
Background: Oesophageal adenocarcinoma (OAC) is a lethal cancer with an overall 5-year survival of Summary: New research on the use of epidemiologic and clinical data has allowed the creation of risk-prediction algorithms to identify the population at risk. In addition, newer less-invasive devices such as transnasal endoscopy, Cytosponge, volumetric laser endomicroscopy, and volatile organic compounds are emerging as promising options to allow screening in the primary care setting. Finally, there is an opportunity to intervene at the pre-invasive stage with pharmacological strategies to reduce the risk burden. Key Messages: In this review, we provide a critical appraisal of the different screening approaches and chemopreventive strategies and a guide to readers on how to implement research evidence in clinical practice.
- Open Access
- 25 June 2021
- Published by The Korean Society of Gastroenterology in The Korean Journal of Gastroenterology
- Vol. 77 (6) , 309-312
Russell Body Lesions of the Colon: Case Report and Literature Review
Russell bodies (RB) are rare manifestations within the lower gastrointestinal tract. To date, there are only three other reported cases of RB lesions of the colon; two were polyps, and the third was a case of a multifocal RB lesion of the gastrointestinal tract. This paper reports a case of a tubulovillous adenoma with RB of the sigmoid colon in a patient diagnosed incidentally as part of the UK National Health Service Bowel Cancer Screening Programme. A thorough hematological investigation is required to exclude hematological malignancies because of its association with plasma cell neoplasm. These lesions should undergo clonality analysis to exclude the monoclonal proliferation of plasma cells. Ideally, a bone marrow aspirate and investigations for amyloidosis should be performed to exclude underlying hematological malignancies.
- 25 June 2021
- Published by The Korean Society of Gastroenterology in The Korean Journal of Gastroenterology
- Vol. 77 (6) , 309-312
Open AccessRussell Body Lesions of the Colon: Case Report and Literature Review
Russell bodies (RB) are rare manifestations within the lower gastrointestinal tract. To date, there are only three other reported cases of RB lesions of the colon; two were polyps, and the third was a case of a multifocal RB lesion of the gastrointestinal tract. This paper reports a case of a tubulovillous adenoma with RB of the sigmoid colon in a patient diagnosed incidentally as part of the UK National Health Service Bowel Cancer Screening Programme. A thorough hematological investigation is required to exclude hematological malignancies because of its association with plasma cell neoplasm. These lesions should undergo clonality analysis to exclude the monoclonal proliferation of plasma cells. Ideally, a bone marrow aspirate and investigations for amyloidosis should be performed to exclude underlying hematological malignancies.
- Open Access
- 22 January 2020
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 08 (02) , E189-E195
Standard versus simplified radiofrequency ablation protocol for Barrett’s esophagus: comparative analysis of the whole treatment pathway
Background and study aims The standard radiofrequency ablation (RFA) protocol for Barrett’s esophagus (BE) encompasses an intermediary cleaning phase between two ablation sessions. A simplified protocol omitting the cleaning phase is less labor-intensive but equally effective in studies based on single ablation procedures. The aim of this study was to compare efficacy and safety of the standard and simplified RFA protocols for the whole treatment pathway for BE, including both circumferential and focal devices. Patients and methods We performed a retrospective analysis of prospectively collected data on patients receiving RFA between January 2007 and August 2017 at two institutions. Outcomes assessed were: 1) complete remission of dysplasia (CR-D) and intestinal metaplasia (CR-IM) at 18 months; and 2) rate of esophageal strictures. Results One hundred forty-five patients were included of whom 73 patients received the standard and 72 patients received the simplified protocol. CR-D was achieved in 94.5 % and 95.8 % of patients receiving the standard and simplified protocol, respectively (P = 0.71). CR-IM was achieved in 84.9 % and 77.8 % of patients treated with the standard and simplified protocol, respectively (P = 0.27). Strictures were significantly more common among patients who received the simplified protocol (12.5 %) compared to the standard protocol (1.4 %; P = 0.008). The median number of esophageal dilations was one. Conclusion The simplified RFA protocol is as effective as the standard protocol in eradicating BE but carries a higher risk of strictures. This needs to be taken into account, particularly in patients with higher pretreatment risk of strictures, such as those with esophageal narrowing from previous endoscopic mucosal resection (EMR).
- 22 January 2020
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 08 (02) , E189-E195
Open AccessStandard versus simplified radiofrequency ablation protocol for Barrett’s esophagus: comparative analysis of the whole treatment pathway
Background and study aims The standard radiofrequency ablation (RFA) protocol for Barrett’s esophagus (BE) encompasses an intermediary cleaning phase between two ablation sessions. A simplified protocol omitting the cleaning phase is less labor-intensive but equally effective in studies based on single ablation procedures. The aim of this study was to compare efficacy and safety of the standard and simplified RFA protocols for the whole treatment pathway for BE, including both circumferential and focal devices. Patients and methods We performed a retrospective analysis of prospectively collected data on patients receiving RFA between January 2007 and August 2017 at two institutions. Outcomes assessed were: 1) complete remission of dysplasia (CR-D) and intestinal metaplasia (CR-IM) at 18 months; and 2) rate of esophageal strictures. Results One hundred forty-five patients were included of whom 73 patients received the standard and 72 patients received the simplified protocol. CR-D was achieved in 94.5 % and 95.8 % of patients receiving the standard and simplified protocol, respectively (P = 0.71). CR-IM was achieved in 84.9 % and 77.8 % of patients treated with the standard and simplified protocol, respectively (P = 0.27). Strictures were significantly more common among patients who received the simplified protocol (12.5 %) compared to the standard protocol (1.4 %; P = 0.008). The median number of esophageal dilations was one. Conclusion The simplified RFA protocol is as effective as the standard protocol in eradicating BE but carries a higher risk of strictures. This needs to be taken into account, particularly in patients with higher pretreatment risk of strictures, such as those with esophageal narrowing from previous endoscopic mucosal resection (EMR).
- 5 November 2019
- Published by American Medical Association (AMA) in JAMA
- Vol. 322 (17) , 1715
One vs 12 Months of Dual Antiplatelet Therapy for Patients After Percutaneous Coronary Intervention
To the Editor The STOPDAPT-2 (Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent 2) study reported noninferi
- 5 November 2019
- Published by American Medical Association (AMA) in JAMA
- Vol. 322 (17) , 1715
One vs 12 Months of Dual Antiplatelet Therapy for Patients After Percutaneous Coronary Intervention
To the Editor The STOPDAPT-2 (Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent 2) study reported noninferi
- 1 August 2016
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 14 (4) , e435-e439
Well-Differentiated Papillary Mesothelioma of the Tunica Vaginalis: Case Report and Systematic Review of Literature
- 1 August 2016
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 14 (4) , e435-e439
Well-Differentiated Papillary Mesothelioma of the Tunica Vaginalis: Case Report and Systematic Review of Literature